


## (S,R,S)-AHPC-C8-NH2 hydrochloride

Cat. No.:	HY-133487A
CAS No.:	2376139-49-8
Molecular Formula:	C <sub>31</sub> H <sub>48</sub> ClN <sub>5</sub> O <sub>4</sub> S
Molecular Weight:	622.26
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology <sup>[1]</sup> .
IC <sub>50</sub> & Target	VHL
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Jian Jin, et al. Serine threonine kinase (akt) degradation / disruption compounds and methods of use. Patent WO2019173516A1.
- [2]. Scheepstra M, et al. Bivalent Ligands for Protein Degradation in Drug Discovery. Comput Struct Biotechnol J. 2019;17:160-176. Published 2019 Jan 25.
- [3]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA